Faculty and Student Publications
Document Type
Article
Publication Date
1-1-2022
Abstract
While overall survival with multiple myeloma (MM) has improved, patients suffer from overwhelming tumor burden, MM-associated comorbidities, and frequent relapses requiring administration of salvage therapies. As a result, this vicious cycle is often characterized by cumulative immunodeficiency stemming from a combination of disease- and treatment-related factors leading to neutropenia, T-cell deficiency, and hypogammaglobulinemia. Infectious etiologies differ based on the duration of MM and treatment-related factors, such as number of previous treatments and cumulative dose of corticosteroids. Herein, we present the case of a patient who was receiving pomalidomide without concomitant corticosteroids for MM and was later found to have cryptococcosis, as well as findings from a literature review. Most cases of cryptococcosis are reported in patients with late-stage MM, as well as those receiving novel anti-myeloma agents, such as pomalidomide, in combination with corticosteroids or following transplantation. However, it is likely cryptococcosis may be underdiagnosed in this population. Due to the cumulative immunodeficiency present in patients with MM, clinicians must be suspicious of cryptococcosis at any stage of MM.
Relational Format
journal article
Recommended Citation
Chastain, D. B., Golpayegany, S., Henao-Martínez, A. F., Jackson, B. T., Stoudenmire, L. L., Bell, K., Stover, K. R., & Franco-Paredes, C. (2022). Cryptococcosis in a patient with multiple myeloma receiving pomalidomide: A case report and literature review. Therapeutic Advances in Infectious Disease, 9, 204993612211126. https://doi.org/10.1177/20499361221112639
DOI
10.1177/20499361221112639
Accessibility Status
Searchable text